4 research outputs found
Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America
Background: The T-20 vs. Optimized Regimen Only Study 1 (TORO 1) was a randomized, open-label,
phase 3 study of enfuvirtide (T-20), a human immunodeficiency virus type 1 (HIV-1)
fusion inhibitor.
Methods: Patients from 48 sites in the United States, Canada, Mexico, and Brazil with at least six
months of previous treatment with agents in three classes of antiretroviral drugs, resistance
to drugs in these classes, or both, and with at least 5000 copies of HIV-1 RNA
per milliliter of plasma were randomly assigned in a 2:1 ratio to receive enfuvirtide plus
an optimized background regimen of three to five antiretroviral drugs or such a regimen
alone (control group). The primary efficacy end point was the change in the plasma
HIV-1 RNA level from base line to week 24.
Results: A total of 501 patients underwent randomization, and 491 received at least one dose of
study drug and had at least one measurement of plasma HIV-1 RNA after treatment
began. The two groups were balanced in terms of the median base-line HIV-1 RNA
level (5.2 log10 copies per milliliter in both groups), median CD4+ cell count (75.5
cells per cubic millimeter in the enfuvirtide group, and 87.0 cells per cubic millimeter
in the control group), demographic characteristics, and previous antiretroviral therapy.
At 24 weeks, the least-squares mean change from base line in the viral load (intention-
to-treat, last observation carried forward) was a decrease of 1.696 log10 copies
per milliliter in the enfuvirtide group, and a decrease of 0.764 log10 copies per milliliter
in the control group (P<0.001). The mean increases in CD4+ cell count were 76
cells per cubic millimeter and 32 cells per cubic millimeter, respectively (P<0.001).
Reactions at the site of the injections were reported by 98 percent of patients receiving
enfuvirtide. There were more cases of pneumonia in the enfuvirtide group than in the
control group.
Conclusions: The addition of enfuvirtide to an optimized antiretroviral regimen provided significant
antiretroviral and immunologic benefit through 24 weeks in patients who had previously
received multiple antiretroviral drugs and had multidrug-resistant HIV-1 infection
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks
Antiretroviral tolerability is a critical factor contributing to treatment outcome. The T-20 Versus Optimized Background Regimen Only (TORO) studies assessed the safety and efficacy of enfuvirtide in treatment-experienced HIV-1-infected patients. A total of 997 patients were randomized at a 2:1 ratio to an optimized background antiretroviral regimen plus enfuvirtide (n = 663) or an optimized background regimen alone (control group; n = 334). Control patients could switch to enfuvirtide on virologic failure. In total, 26.5% of patients randomized to enfuvirtide and 36.6% to the control group discontinued study treatment before week 48; the percentage of patients withdrawn for safety reasons (including adverse events [AEs], deaths, and laboratory abnormalities) was 14.0% in the enfuvirtide group and 11.6% in the control group. Injection site reactions (ISRs) occurred in 98% of enfuvirtide patients and led to treatment discontinuation in 4.4%. Treatment-related (defined as possibly, probably, or remotely) AE rates per 100 patient-years were lower with enfuvirtide (96.2) than in the control group (149.9); diarrhea, nausea, and fatigue, the most frequently reported AEs, were significantly less frequent with enfuvirtide than in the control group. Pneumonia was significantly more frequent in patients treated with enfuvirtide (6.7 vs. 0.6 events per 100 patient-years), although the incidence was within expected ranges for this population. Lymphadenopathy was also higher in enfuvirtide-treated patients (7.1 vs. 1.2 events per 100 patient-years) for control patients. The addition of enfuvirtide to an optimized background regimen does not exacerbate AEs commonly associated with antiretrovirals. ISRs limited treatment in <5% of patient